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ABSTRACT 
 
The application of naked DNA containing type I interferon (IFN) transgenes is a promising potential therapeutic 
approach for controlling chronic viral infections. Herein, we detail the application of this approach that has been 
extensively used to restrain ocular HSV-1 infection, for antagonizing vaginal HSV-2 i n f e c t i o n .  W e  s h o w  t h a t  
application of IFN-α1, -α5, and –β transgenes to vaginal mouse lumen 24 hours prior to HSV-2 infection reduces HSV-
2 mediated mortality by 2.5 to 3-fold. However, other type I IFN transgenes (IFN- α4, -α5, -α6, and –α9) are non 
effectual against HSV-2. We further show that the efficacy of IFN-α1 transgene treatment is independent of CD4+ T 
l y m p h o c y t e s .  H o w e v e r ,  i n  m i c e  d e p l e t e d  o f  C D 8 +  T  l y m p h o c y t e s ,  t h e  a b i l i t y  o f  I F N - α1 transgene treatment to 
antagonize HSV-2 was lost. 
 
 
INTRODUCTION 
 
Herpes simplex virus 2 (HSV-2) is a sexually transmitted 
disease that causes painful recurrent mucosal cutaneous 
ulcerations. The overall estimated seroprevalence among 
humans living in the United States is 21.9% (1). Being a 
disease process with a disparate distribution in 
populations, HSV-2 affects even a higher percentage of 
humans of female gender, low socioeconomic status, and 
African or Mexican heritage (1, 2). Other risk factors for 
HSV-2 infection include: use of contraceptives in women 
(3, 4), minimal education, and number of sexual patterns 
(5). The development of genital ulcerations also 
augments the risk of human immunodeficiency virus 
(HIV) transmission (6); reciprocally, the infectiousness of 
HIV also increases during periods of HSV-2 reactivation 
(6).  
 
Like other herpes viruses humans are the predominate 
host for HSV-2, and the virus establishes a lifelong 
infection. HSV-2 spreads from one human host to 
another via transmission of infectious virus in mucosal 
secretions at epithelial surfaces. Virus initially replicates 
within epithelial tissue in the initial site of inoculation 
prior to entering associated sensory ganglia, such as the 
sacral ganglia. Within sensory ganglia neurons, HSV-2 
establishes a latent infection, from which the virus 
periodically reactivates and re-infects the initial site of 
infection. Episodic reactivations transpire as many as 4-5 
times per year. However, recrudescent viral shedding is 
also common (7-9).  
 
While HSV-2 is most commonly coupled with urogenital 
tract lesions, the virus can also inoculate mucosal 
epithelium in the upper body and establish latent     
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infection in associated sensory neurons. A number of 
ocular diseases originate from HSV-2 infection including: 
anterior uveitis, stromal keratitis, and retinal necrosis 
(10, 11). HSV-2 can further spread from sensory ganglia 
to the CNS causing potentially lethal meningitis and 
encephalitis (12). Substantial increases in the incidence of 
HSV-2 infections in recent years have prompted studies 
to develop vaccinations and anti-viral therapies to curb 
this epidemic (13, 14). 
 
Naked DNA vaccines encoding viral antigens or immune 
system adjuvants, such as chemokines have been tested 
as experimental vaccines against herpes simplex viruses 
1 and 2 (15-21) and other viruses. A number of 
advantages with DNA vaccination have been 
enumerated including: relatively inexpensive vaccine 
preparation and resistance to temperatures over 50°C, 
both of which are critical factors for vaccination in 
resource poor populations, where up to 69% of women 
have serological evidence of HSV-2 (22). To better 
understand mechanisms of endogenous anti-herpes 
pathways, our lab utilizes plasmid DNA encoding type I 
interferon (IFN) transgenes as a means to control virus 
replication and spread. 
 
IFNs are endogenous anti-viral cytokines elicited in 
response to viral infection. Transfection of mice with 
type I IFN transgenes is an established approach to 
reduce HSV-1 mediated mortality (23). Furthermore, the 
ability of type I IFN transgenes to antagonize HSV-1 
relies on OAS/RNase L pathway induction (23), a known 
downstream IFN effector, which inhibits viral infectivity 
via RNA degradation. Transfection of mice with IFN-α1 
transgenes also enhances cumulative survival of mice 
vaginally infected with HSV-2 (24). However, the facility 
of IFN-α1 transgene treatment to antagonize HSV-2 does 
not require induction of the OAS/RNase L pathway. 
Conversely, the ability of IFN-α1 transgene to antagonize 
H S V - 2  r e q u i r e s  i n d u c t i o n  o f  p r o t e i n  k i n a s e  R ,  a n  I F N  
inducible anti-viral pathway that inhibits protein 
synthesis (25). Presently, we detail the methodology for 
utilizing type I IFN transgenes to manage vaginal HSV-2 
infection in a mouse model. We further show that the 
effectiveness of IFN-α1 transgenes requires CD8+ T 
lymphocytes. Finally, we assess the significance of other 
type I IFN trangenes at preventing HSV-2 mediated 
mortality. 
 
MATERIALS AND METHODS 
 
Treatment of mice 
 
Animal treatment was consistent with the National 
Institutes of Health Guidelines on the Care and Use of 
Laboratory Animals. All procedures were approved by 
the University of Oklahoma Health Sciences Center and 
Dean A McGee Eye Institutional Animal Care and Use 
Committees. Female ICR mice (Sprague Dawley, from 
Harlan Sprague Dawley), ages 6-8 weeks were 
subcutaneously injected with 2 mg DepoProvera 5 d 
prior to infection, since progesterone facilitates vaginal 
HSV-2 infection (26, 27). Four days after administration 
of DepoProvera, mice were anesthetized by i.p. injection 
with xylazine (2mg/ml; 6.6 ml/kg) and ketamine (30 
mg/ml; 100 mg/kg). Subsequently, vaginal mucous was 
removed with sterile calcium alginate fiber tipped swabs 
(Fisher Scientific) prior to vaginal transfection with IFN 
transgenes - local administration of 100 µg DNA in 20 µl 
TE buffer - 10 mM Tris, 1 mM ethylendiaminetetracetic 
acid (EDTA), pH 8.0. Five days after administration of 
DepoProvera, mice were anesthetized (as described 
previously) and vaginal mucous was again removed 
prior to infecting vaginal lumen with 2,400 plaque 
forming units (PFU) HSV-2. Mice were monitored over 
30 d post-infection (p.i.), and mortality was recorded for 
each group of animals.  
 
Virus and cells 
 
All culture media reagents were from Life Technologies, 
Gaithersburg, MD. Vero cells (African green monkey 
kidney), obtained from the American Type Culture 
Collection (Manassas, VA) were cultured in RPMI 1640, 
supplemented with 5% FBS, 2 % antibiotic/antimycotic, 
and 0.2 % gentamicin. Cells cultures were incubated in 
an atmosphere of 37°C, 5% CO2, and 95% humidity. 
 
A clinical isolate of HSV-2 was obtained from University 
Hospital (New Orleans, LA) and propagated on Vero 
cells (28). Specifically, confluent monolayers of Vero 
cells, grown in two T-175 culture flasks, were infected 
with 0.1 MOI HSV-2, diluted in 6 mls prepared RPMI 
media. After 1 hour, medium was replaced with 20 ml 
fresh complete medium. When 90% cytopathic effect was 
observed, cells were subjected to one freeze thaw cycle.     
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Cells were collected and non viral cellular debris was 
pelleted away from virus by centrifugation for 15 
minutes at 4,000 rpm. Supernatant was further clarified 
by one more centrifugation for 15 minutes at 4,000 rpm. 
HSV-2 was pelleted from the clarified supernatant by 
centrifugation at 20,000 g x 2 h. Viral pellets were 
washed two times with sterile 1x phosphate buffered 
saline (PBS) and viral suspensions were combined in 1 
ml sterile 1x PBS. Aliquots (50 µl) were stored at -80°C. 
Viral titer in triplicate was determined by transferring 
logarithmic dilutions (10-5 to 10-9) of HSV-2, diluted in 
complete medium, onto confluent Vero cells in 24-well 
plates. After 1 hour, medium was replaced with 0.5 % 
methylcellulose, diluted in complete medium. Viral 
plaque formation was assessed after a 32 h incubation 
period and recorded as PFU/ml. 
 
CD4+ and CD8+ T cell depletion 
 
CD4+ and CD8+ T lymphocytes were depleted and the 
depletion of T lymphocyte populations was monitored as 
previously described (29). 
 
Plasmid DNA construction 
 
The plasmid backbone, pkCMV (vector) was obtained 
from Vical Inc., San Diego, CA. This vector consists of: a) 
plasmid double stranded DNA backbone, b) immediate 
early CMV promoter for expression in mammalian cells, 
c) intron with splice donor/splice acceptor where the 
murine IFN transgenes (575-626 bp) were inserted (30), 
d) ori sequence for replication in mammalian cells, e) 
SV40 polyadenlyation signal, f) pUC origin of replication 
for propagation in Escherichia coli g) kanamycin 
resistance gene for selection in E. Coli. Further details 
about the original source and cloning procedures (30-34) 
have been described. Plasmid constructs were 
transformed into E. coli strain INVαF’ (Invitrogen, 
Carlsbad, CA) and products were analyzed by agarose 
gel electrophoresis (30). More details about plasmid 
production and purification can be found in the 
protocols section. 
 
Statistical analysis 
 
Survival studies were analyzed for significance (p≤0.05) 
by the Mann-Whitney U rank sum test, using the 
GBSTAT program (Dynamic Microsystems, 
Gaithersburg, MD).  
RESULTS 
 
In ICR mice, which are highly susceptible to the lethal 
effects of herpes (35), we previously showed that 
transfection of mouse corneas with IFN-α1 and –β 
transgenes, 24 hours prior to HSV-1 infection, enhanced 
the cumulative survival of mice by 3-fold (23). Other type 
I IFN transgene treatments (IFN-α5 and –α6) were not 
effective at preventing the lethal effects of HSV-1 
infection (23). To further explore whether type I IFN 
transgene subtypes also provide diverse levels of 
protection against HSV-2 infection, survival studies with 
type I IFN transgene treatment of female ICR mice, 
vaginally infected with HSV-2 were initiated. The 
c u m u l a t i v e  s u r v i v a l  o f  mice treated with IFN-α1, -α5, 
and –β transgenes, 24 hours prior to vaginal HSV-2 
infection was enhanced by 2.5 to 3-fold (Fig. 1) in 
comparison to mice treated with vector alone (plasmid 
DNA backbone without an IFN transgene). Other IFN 
transgenes (IFN-α4, -α6, and –α9) were not effective at 
reducing HSV-2 mediated mortality (Fig. 1). 
 
 
Fig. 1: A comparison of cumulative survival of mice when treated with IFN-
α1, -α5, and –β transgenes and with vector alone. 
 
Previously, we showed that CD4+ and CD8+ T 
lymphocytes are required for the anti-HSV-1 activity of 
IFN-α1 transgene treatment (29). To determine whether 
both CD4+ and CD8+ T lymphocytes are also required 
for the anti-HSV-2 activity of IFN-α1 transgene 
treatment, CD4+ and CD8+ T lymphocytes were depleted 
in mice hormonally susceptible to HSV-2. In comparison 
to treatment with normal rat serum, the cumulative 
survival of HSV-2 infected mice decreased by 2 and 4-
fold, respectively, following depletion of CD8+ and CD4+ 
T lymphocytes (Fig. 2A). While the absence of both types 
of T lymphocytes negatively affected the survival of 
HSV-2 infected mice, with IFN-α1 transgene treatment, 
the impact of CD4+ T lymphocyte depletion was     
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reversible. Specifically, mortality rates at the end of 30 d 
with IFN-α1 transgene treatment in CD4+ T lymphocyte 
depleted mice as well as mice treated with normal rat 
serum were the same (Fig. 2B). In contrast to this 
o b s e r v a t i o n ,  i n  m i c e  d e p l e t e d  o f  C D 8 +  T  l y m p h o c y t e s ,  
the effectiveness of IFN-α1 transgene treatment was lost. 
With IFN-α1 transgene treatment and CD8+ T 
lymphocyte depletion, survival following HSV-2 
infection decreased 2-fold, in comparison to survival 
with IFN-α1 transgene treatment in mice treated with 
normal rat serum (Fig. 2B). 
 
 
Fig. 2: The treatment of HSV-2 infected mice and cumulative survival and 
the impact of CD4+ T-lymphocyte depletion. 
 
DISCUSSION 
 
Previous work from our lab has shown that IFN 
transgene treatment is effective at reducing herpes 
mediated mortality, inhibiting viral replication, reducing 
viral antigen expression, reducing viral protein synthesis, 
reducing inflammatory leukocyte infiltration, inducing 
interferon stimulated gene expression, and inhibiting 
herpes reactivation (23, 24, 30, 36-41). In applying this 
methodology to antagonize other viruses, it is 
noteworthy that we have found application of transgenes 
24 hours before HSV-1 infection to be more effective than 
earlier time points before infection or transgene 
treatment post-infection (29, 37, 38), with a minimal 
effective dose of 50-100 µg DNA/mouse eye (HSV-1) or 
100 µg DNA/mouse vagina (HSV-2). The usefulness of 
transgene treatment, with respect to time of infection, is 
likely related to the transient nature of transgene 
expression following transfection. With IFN-α1 
transgene treatment, transgene expression is only 
detected 24-72 hours post-transfection (37). The short-
term nature of transgene expression following 
transfection using a naked DNA approach is a known 
obstacle to DNA based vaccine strategies (42). Transgene 
inoculation intramuscularly provides longer term 
expression (43). 
 
In addition to length of expression, efficiency of 
transfection is also challenging. Following plasmid DNA 
transfection, only a small fraction of DNA molecules 
actually transfect target cells (42). Thus, high plasmid 
doses are typically used in animal models (42, 44). In our 
system we have shown, using a LacZ reporter gene, 
evidence of gene expression in vaginal epithelium at 3 
days following application of plasmid DNA (24). The 
plasmid DNA also trafficks to the spinal cord and 
lymphatic tissue, 24 hours post-transfection of HSV-2 
infected tissue (24). Coupled with the efficiency of 
transfection, we have encountered difficulties measuring 
biologically active levels of IFN following transfection of 
vaginal epithelium. However, we are able to detect 
increased levels of interferon stimulated gene expression 
using real time PCR (25). Ongoing efforts to overcome 
obstacles related to length and efficiency of transfection 
include: improving transfection efficiency and protecting 
DNA from degradation (42).  
 
Transient expression is considered advantageous in the 
respect that foreign DNA is less likely to insert into the 
host genome (45). Even so, it is a critical consideration to 
develop delivery systems that target gene delivery to 
appropriate tissues. Delivery of IFN-transgenes via a 
mucosal route is a useful approach to study immune 
response because mucosal surfaces are the most likely 
site for herpes to invade hosts, and application of 
plasmid DNA is known to induce local and systemic 
cellular and humoral immunity (45). Related to this, it is 
vital to use a vector (control) in each experiment to 
separate IFN-inducible effects from immune response 
elicited by CpG motifs in the plasmid DNA backbone. In     
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our model following topical application of plasmid DNA 
to vagina, reporter gene expression is detected locally 
and also in lymph node and spinal cord (24). Likewise, 
following topical application of plasmid DNA to eye, 
reporter gene expression is detected locally, with the 
innervating sensory ganglia (i.e., trigeminal ganglia), and 
also in spleen (29). Stimulation of humoral and cellular 
immunity with plasmid DNA is considerably less 
harmful than utilizing attenuated virus (46), and the 
adjuvant effect of CpG DNA is considered beneficial for 
immune studies because a separate adjuvant is not 
required. Nevertheless, identification of critical sites of 
targeted delivery along with increased delivery 
efficiency would enable the smallest effective dose. 
Smaller doses targeted to specific cells both reduce 
random distribution of foreign genes and increase 
therapeutic cost effectiveness. 
 
Attempts to control delivery of plasmid DNA include 
use of polymers that condense plasmid DNA and 
increase diffusion through plasmid membrane, and use 
of cell-specific targeting ligands (47). Cell-specific 
targeting has been achieved by conjugating peptide to 
proteins that function to condense plasmid DNA. 
Moreover, conjugation of certain antibodies to lipids has 
been shown to increase efficiency of cell uptake. For 
example, conjugation of anti-transferrin antibodies to 
liposome-DNA complexes has been shown to increase 
gene delivery to cornea (48). Conjugation of transferrin 
to polyethyleneimine has further been shown to enhance 
transfection efficiency, likely via enhanced endocytosis 
(48).  
 
Other attempts to control transgene expression involve 
development of tissue and cell-specific expression 
systems. Our IFN transgenes are under the control of a 
promiscuous viral promoter, CMV. This factor combined 
with distribution of plasmid DNA both locally as well as 
to lymphatic system, potentially leads to more 
widespread distribution of IFN than required for 
controlling site-specific herpes pathogenesis. Systemic 
release of high levels of IFN is known to cause numerous 
unwanted side effects including: fever, chills, headaches, 
achy muscles, diarrhea, loss of appetite, anemia, 
increased bleeding and bruising, and birth defects. 
Development of a more site-specific IFN-based anti-viral 
therapy with controlled expression is a long term goal. 
Generally, non-viral based transfection agents are not 
effective for delivering genes to the nervous system. Use 
of replication defective herpes amplicons or other 
replication defective neurotropic viruses show promise 
as potential vectors for delivery of anti-viral genes 
specifically to sites of herpes infection. 
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PROTOCOLS 
 
Protocol for plasmid purification: A slightly modified protocol from that provided with the Quantum Prep Plasmid 
Maxiprep Kit (Bio-Rad Laboratories, Inc.) is listed below. Further details about plasmid purification have been 
described (49). 
 
Re-suspension buffer: 50 mM d-glucose, 10 mM EDTA, 25 mM Tris HCl (pH 8.0), and 2 mg/ml lysozyme 
 
Alkaline Lysis solution: 0.2 N NaOH and 1% SDS in sterile double distilled water 
 
Wash buffer: 200 mM NaCl, 40 mM Tris HCl, 4 mM EDTA, adjust pH to 7.5, and add an equal volume of 100% 
ethanol 
  
Neutralization buffer: 4 M potassium-acetate (pH 4.8) 
 
Weigh 23.55 g potassium acetate. Add 66 ml sterile double distilled water and 28.5 ml glacial acetic acid. Titrate with 
approximately 1.5 ml concentrated HCl to pH 4.8. Adjust volume to 100 ml with sterile double distilled water. 
 
TE buffer: 10 mM Tris, 1 mM EDTA, pH 8.0 
 
1.  Grow bacteria containing each interferon transgene in 1L of sterile Terrific broth (Bio 101 Systems), containing 50 
µg/ml kanamycin, by incubating overnight (14-16 h) at 37°C with shaking (200 rpm). 
2.  Pellet bacteria by centrifugation (5 minutes at 5,000g) in 500 ml sterile centrifuge bottles. Cells may be frozen at 
this point. 
3.  Thaw cells at room temperature. Re-suspend cells by adding 15 ml cell re-suspension buffer containing DNase 
free RNase A (40 units/ml) to the pellet obtained from each 500 ml of bacteria broth. Pipet up and down until the 
cells are completely re-suspended.  
4.  Add alkaline lysis buffer, containing a high concentration of anionic detergent (23 ml/pellet obtained from 500 ml 
bacteria broth) to lyse cell membranes, denature chromosomal DNA and proteins, and release plasmid DNA into 
the supernatant. Make sure that SDS has not precipitated out of solution by making the solution fresh, or warm 
solution to 37°C prior to use to dissolve any visible precipitate. Mix by swirling the bottle. Avoid vortexing at any 
time in the procedure to avoid shearing DNA. 
5.  Neutralize by addition of 15 ml neutralization solution to return the pH to normal and allow the 2 strands of 
plasmid DNA to return to the native state. Make sure there is no visible precipitate in the neutralization solution; 
if precipitate is visible, warm to 37°C prior to use. 
6.  Centrifuge at 10,000 g x 30 minutes to remove precipitated membrane, SDS, protein, and chromosomal DNA. Pour 
supernatant, containing plasmid DNA into a new centrifuge bottle. Centrifuge a second time at 10,000g x 10 
minutes to remove any remaining debris. 
7.  Bind plasmid DNA to a diatomaceous earth based DNA binding matrix by addition of 20 ml re-suspended matrix 
to cleared lysate. Swirl gently for 30 seconds. Allow DNA to bind for 5 minutes, then centrifuge for 5 minutes at 
3,000 g to pellet the matrix.  
8.  Wash matrix 4 times with one volume of wash buffer by centrifugation for 5 min at 4,000 rpm. 
9.  Elute DNA with 5 ml sterile water x 2 -3 washes. Collect separate fractions from each wash. Typically one of the 
fractions will be more pure than the others. 
10.  Precipitate plasmid DNA by adding 1/18th volume of 5 M NaCl and 2 volumes of cold 95-100% ethanol. Precipitate 
DNA overnight in the fridge. 
11.  Pellet DNA by centrifugation for 30 minutes at 10,000g. 
12.  Wash pellet by addition of 1 ml 70% ethanol. Tap tube to re-suspend plasmid DNA. Decant into microcentrifuge 
tube and centrifuge at 10,000 rpm for 1 minute. Repeat 5 times. 
13.  Dry the pellet before re-suspending in TE buffer. 
 